| 18F-FDG | 18-fluoride-fluorodeoxyglucose |
| 68Ga | 68-gallium |
| 177Lu | 177-lutetium |
| ∆TLP | Change from baseline to post-RLT in total lesion PSMA |
| ∆SUVmean | Change in mean standardized uptake value |
| ADT | Androgen deprivation therapy |
| ALP | Alkaline phosphatase |
| CT | Computed tomography |
| ECOG | Eastern Cooperative Oncology Group |
| mCRPC | Metastatic castration-resistant prostate cancer |
| MIP | Maximum intensity projection |
| NA | Not available |
| NAAD | Novel androgen axis drugs |
| NS | Not studied |
| PERCIST | PET Response in Solid Tumor Criteria |
| PET | Postron emission tomography |
| PR | Partial response |
| PSA | Prostate-specific antigen |
| PSMA | Prostate-specific membrane antigen |
| RLT | Radioligand therapy |
| SUVmax | Maximum standardized uptake value |
| SUVmean | Mean standardized uptake value |
| TLP | Total lesion PSMA |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.